vs

Side-by-side financial comparison of Arteris, Inc. (AIP) and Avidity Biosciences, Inc. (RNA). Click either name above to swap in a different company.

Arteris, Inc. is the larger business by last-quarter revenue ($20.1M vs $12.5M, roughly 1.6× Avidity Biosciences, Inc.). Arteris, Inc. runs the higher net margin — -42.2% vs -1398.3%, a 1356.1% gap on every dollar of revenue. On growth, Avidity Biosciences, Inc. posted the faster year-over-year revenue change (434.0% vs 30.0%). Arteris, Inc. produced more free cash flow last quarter ($3.0M vs $-156.9M). Over the past eight quarters, Avidity Biosciences, Inc.'s revenue compounded faster (138.5% CAGR vs 24.7%).

Arteris, Inc. is a multinational technology company headquartered in Campbell, California. It develops the network-on-chip (NoC) IP and system-on-chip (SoC) integration automation software that is used to create semiconductor chip and chiplet designs for a variety of devices, particularly in automotive electronics, artificial intelligence, machine learning, enterprise computing, communications, consumer, industrial, and aerospace & defense markets. The company specializes in the development a...

Eli Lilly and Company, doing business as Lilly, is an American multinational pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries. The company was founded in 1876 by Eli Lilly, a pharmaceutical chemist and Union army veteran during the American Civil War for whom the company was later named.

AIP vs RNA — Head-to-Head

Bigger by revenue
AIP
AIP
1.6× larger
AIP
$20.1M
$12.5M
RNA
Growing faster (revenue YoY)
RNA
RNA
+404.0% gap
RNA
434.0%
30.0%
AIP
Higher net margin
AIP
AIP
1356.1% more per $
AIP
-42.2%
-1398.3%
RNA
More free cash flow
AIP
AIP
$159.9M more FCF
AIP
$3.0M
$-156.9M
RNA
Faster 2-yr revenue CAGR
RNA
RNA
Annualised
RNA
138.5%
24.7%
AIP

Income Statement — Q4 FY2025 vs Q3 FY2025

Metric
AIP
AIP
RNA
RNA
Revenue
$20.1M
$12.5M
Net Profit
$-8.5M
$-174.4M
Gross Margin
90.8%
Operating Margin
-42.0%
-1513.5%
Net Margin
-42.2%
-1398.3%
Revenue YoY
30.0%
434.0%
Net Profit YoY
-3.7%
-117.0%
EPS (diluted)
$-0.19
$-1.27

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
AIP
AIP
RNA
RNA
Q4 25
$20.1M
Q3 25
$17.4M
$12.5M
Q2 25
$16.5M
$3.8M
Q1 25
$16.5M
$1.6M
Q4 24
$15.5M
$3.0M
Q3 24
$14.7M
$2.3M
Q2 24
$14.6M
$2.0M
Q1 24
$12.9M
$3.5M
Net Profit
AIP
AIP
RNA
RNA
Q4 25
$-8.5M
Q3 25
$-9.0M
$-174.4M
Q2 25
$-9.1M
$-157.3M
Q1 25
$-8.1M
$-115.8M
Q4 24
$-8.2M
$-102.3M
Q3 24
$-7.7M
$-80.4M
Q2 24
$-8.3M
$-70.8M
Q1 24
$-9.4M
$-68.9M
Gross Margin
AIP
AIP
RNA
RNA
Q4 25
90.8%
Q3 25
89.9%
Q2 25
89.4%
Q1 25
90.8%
Q4 24
89.8%
Q3 24
90.1%
Q2 24
90.0%
Q1 24
88.7%
Operating Margin
AIP
AIP
RNA
RNA
Q4 25
-42.0%
Q3 25
-50.1%
-1513.5%
Q2 25
-50.0%
-4448.7%
Q1 25
-46.6%
-8360.9%
Q4 24
-45.9%
-4069.6%
Q3 24
-53.8%
-4200.9%
Q2 24
-51.1%
-4040.4%
Q1 24
-70.5%
-2178.6%
Net Margin
AIP
AIP
RNA
RNA
Q4 25
-42.2%
Q3 25
-51.6%
-1398.3%
Q2 25
-55.3%
-4089.3%
Q1 25
-49.1%
-7360.0%
Q4 24
-53.0%
-3439.5%
Q3 24
-52.2%
-3441.7%
Q2 24
-57.2%
-3461.8%
Q1 24
-72.6%
-1943.4%
EPS (diluted)
AIP
AIP
RNA
RNA
Q4 25
$-0.19
Q3 25
$-0.21
$-1.27
Q2 25
$-0.22
$-1.21
Q1 25
$-0.20
$-0.90
Q4 24
$-0.19
$-0.80
Q3 24
$-0.20
$-0.65
Q2 24
$-0.22
$-0.65
Q1 24
$-0.25
$-0.79

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
AIP
AIP
RNA
RNA
Cash + ST InvestmentsLiquidity on hand
$33.9M
$350.2M
Total DebtLower is stronger
Stockholders' EquityBook value
$-14.6M
$1.9B
Total Assets
$115.0M
$2.1B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
AIP
AIP
RNA
RNA
Q4 25
$33.9M
Q3 25
$39.0M
$350.2M
Q2 25
$38.0M
$243.9M
Q1 25
$42.3M
$254.2M
Q4 24
$43.8M
$219.9M
Q3 24
$48.7M
$370.2M
Q2 24
$45.8M
$575.8M
Q1 24
$44.8M
$471.4M
Stockholders' Equity
AIP
AIP
RNA
RNA
Q4 25
$-14.6M
Q3 25
$-11.4M
$1.9B
Q2 25
$-7.5M
$1.2B
Q1 25
$-4.8M
$1.3B
Q4 24
$-1.2M
$1.4B
Q3 24
$2.2M
$1.5B
Q2 24
$5.3M
$1.2B
Q1 24
$9.5M
$830.9M
Total Assets
AIP
AIP
RNA
RNA
Q4 25
$115.0M
Q3 25
$107.7M
$2.1B
Q2 25
$106.9M
$1.4B
Q1 25
$98.3M
$1.5B
Q4 24
$106.1M
$1.6B
Q3 24
$97.7M
$1.6B
Q2 24
$96.4M
$1.3B
Q1 24
$101.4M
$951.5M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
AIP
AIP
RNA
RNA
Operating Cash FlowLast quarter
$3.2M
$-156.2M
Free Cash FlowOCF − Capex
$3.0M
$-156.9M
FCF MarginFCF / Revenue
15.1%
-1257.6%
Capex IntensityCapex / Revenue
0.7%
5.7%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$5.3M
$-592.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
AIP
AIP
RNA
RNA
Q4 25
$3.2M
Q3 25
$3.2M
$-156.2M
Q2 25
$-2.5M
$-199.7M
Q1 25
$2.9M
$-124.8M
Q4 24
$-2.6M
$-99.9M
Q3 24
$1.1M
$-65.6M
Q2 24
$311.0K
$-65.0M
Q1 24
$477.0K
$-70.4M
Free Cash Flow
AIP
AIP
RNA
RNA
Q4 25
$3.0M
Q3 25
$2.5M
$-156.9M
Q2 25
$-2.8M
$-203.0M
Q1 25
$2.7M
$-128.6M
Q4 24
$-2.7M
$-103.8M
Q3 24
$1.1M
$-67.3M
Q2 24
$264.0K
$-65.5M
Q1 24
$281.0K
$-71.3M
FCF Margin
AIP
AIP
RNA
RNA
Q4 25
15.1%
Q3 25
14.2%
-1257.6%
Q2 25
-17.2%
-5277.1%
Q1 25
16.2%
-8174.3%
Q4 24
-17.3%
-3491.0%
Q3 24
7.4%
-2881.8%
Q2 24
1.8%
-3204.6%
Q1 24
2.2%
-2012.3%
Capex Intensity
AIP
AIP
RNA
RNA
Q4 25
0.7%
Q3 25
4.1%
5.7%
Q2 25
2.2%
86.9%
Q1 25
1.1%
238.6%
Q4 24
0.3%
131.7%
Q3 24
0.2%
72.9%
Q2 24
0.3%
26.0%
Q1 24
1.5%
25.8%

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

AIP
AIP

License And Maintenance$17.5M87%
Variable Royalties And Other$2.6M13%

RNA
RNA

Segment breakdown not available.

Related Comparisons